A 42-year-old woman is evaluated in the hospital for persistent fever. She was admitted tw… — USMLE Step 3

A $42$ -year-old woman is evaluated in the hospital for persistent fever. She was admitted two days ago with right-sided flank pain, dysuria, and a temperature of $39.1^\circ\text{C}$ ( $102.4^\circ\text{F}$ ). Her medical history is significant for complex partial seizures, which have been well-controlled on valproic acid for the past five years, and type $2$ diabetes mellitus. Upon admission, she was started on empiric intravenous ceftriaxone for severe pyelonephritis.

Today, her temperature is $38.9^\circ\text{C}$ ( $102.0^\circ\text{F}$ ), blood pressure is $105/65 \text{ mmHg}$ , heart rate is $112 \text{ bpm}$ , and respiratory rate is $18/\text{min}$ . Laboratory studies show a serum creatinine of $1.9 \text{ mg/dL}$ (baseline $0.8 \text{ mg/dL}$ ).

Blood and urine cultures drawn on admission are both growing *Escherichia coli*. The microbiology laboratory confirms that the isolate is an extended-spectrum beta-lactamase (ESBL) producer. The susceptibility profile is as follows:

Ceftriaxone: Resistant
Cefepime: Resistant
Piperacillin-tazobactam: Susceptible
Meropenem: Susceptible
Amikacin: Susceptible

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

A
Switch to intravenous piperacillin-tazobactam
B
Switch to intravenous meropenem and increase the valproic acid dose
Switch to intravenous meropenem and transition valproic acid to levetiracetamAnswer
D
Switch to intravenous amikacin
E
Withhold antibiotic changes until repeat blood cultures confirm persistent bacteremia

Answer

The correct management is to switch to intravenous meropenem and transition valproic acid to levetiracetam.

The patient requires definitive treatment for an ESBL-producing *E. coli* bacteremia. The drugs of choice for severe ESBL infections are carbapenems (e.g., meropenem). However, carbapenems cause a rapid, profound, and irreversible decrease in serum valproic acid concentrations. They inhibit acylpeptide hydrolase, the enzyme responsible for de-glucuronidating valproate in the liver, leading to rapid renal excretion of the valproate-glucuronide complex. Because this interaction can precipitate breakthrough seizures within 24 hours and cannot be reliably managed by simply increasing the valproic acid dose, the correct clinical management is to initiate the lifesaving carbapenem while temporarily transitioning the patient to an alternative antiepileptic agent (such as levetiracetam) that does not interact with meropenem.

Step-by-Step Solution

Analyze the microbiology results and the patient's clinical status.

The patient has ESBL-producing E. coli bacteremia and pyelonephritis, which is not responding to the current resistant empiric therapy (ceftriaxone).

Identifying the resistance mechanism (ESBL) is critical for selecting the definitive antibiotic agent.

Select the optimal antibiotic class for ESBL bacteremia.

Carbapenems (such as meropenem) are the gold standard. Piperacillin-tazobactam should be avoided due to poorer clinical outcomes.

Literature demonstrates that relying on piperacillin-tazobactam for ESBL bacteremia leads to higher mortality, even when reported as susceptible in vitro.

Assess for major pharmacologic interactions and contraindications.

The patient has acute kidney injury (creatinine 1.9 mg/dL), contraindicating amikacin. The patient is on valproic acid, which has a severe, well-documented interaction with carbapenems.

Carbapenems inhibit acylpeptide hydrolase, drastically lowering valproic acid levels and precipitating seizures.

Formulate the comprehensive pharmacologic management plan.

Initiate meropenem to treat the life-threatening bacteremia and simultaneously transition the valproic acid to a non-interacting antiepileptic drug, such as levetiracetam.

This strategy effectively treats the infection while safely mitigating the severe drug-drug interaction.

Key Concept

Management of ESBL bacteremia with a carbapenem and the critical pharmacokinetic interaction between carbapenems and valproic acid.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic